SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin

SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin
SCHOTT Pharma specifies FY 2025 guidance:

• Organic revenue growth for FY 2025 is expected to be around 6.0%, at the lower end of management expectations between 6.0% and 9.0% (“high-single digit”).
• The EBITDA margin for FY 2025 is expected to be around 28.0%, above the previous guidance of “approximately at the level of FY 2024 (26.9%)”.

The above specification is based on preliminary results in the first nine months and the outlook for the full fiscal year 2025.

For further information and preliminary Q3/9M 2025 financial results we refer to our supplemental press release.

The full set of Q3/9M 2025 financial results will be published on August 12, 2025.

Contact
Lea Kaiser 
PR & Communications Manager 
Tel.: +49 (0) 151 68917195 
E-Mail: lea.kaiser@schott.com 
 
Tobias Erfurth 
Head of Investor Relations 
E-Mail: ir.pharma@schott.com 
 
Jasko Terzic, CFA 
Senior Manager Investor Relations 
E-Mail: ir.pharma@schott.com